NASDAQ:AZYO - Nasdaq - US05479K1060 - Common Stock - Currency: USD
NASDAQ:AZYO (9/6/2023, 8:00:01 PM)
1.49
+0.03 (+2.05%)
The current stock price of AZYO is 1.49 USD. In the past month the price decreased by -1.97%. In the past year, price decreased by -79.62%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Aziyo Biologics, Inc. operates as a biotechnology company. The company is headquartered in Silver Spring, Maryland and currently employs 151 full-time employees. The company went IPO on 2020-10-08. The firm has developed a portfolio of regenerative products using both human and porcine tissue that are designed to be as close to natural biological material. The firm operates in four segments: Device Protection, Women's Health, Orthobiologics, and Cardiovascular. Its product portfolio includes CanGaroo, SimpliDerm, ViBone, OsteGro V, Fiber VBM, ProxiCor, Tyke, and VasCure. These products are primarily sold to healthcare providers or commercial partners. In device protection, it sells biological envelopes that form a natural, systemically vascularized pocket for holding implanted electronic devices. In cardiovascular, the Company sells its specialized porcine small intestine submucosa (SIS ECM) for use as an intracardiac and vascular patch. The company also sells human tissue products under contract manufacturing and other arrangements with corporate customers.
AZIYO BIOLOGICS INC-CLASS A
12510 Prosperity Drive, Suite 370
Silver Spring MARYLAND 20904 US
CEO: Ronald Lloyd
Employees: 151
Company Website: https://www.aziyo.com/
Phone: 12402471143.0
The current stock price of AZYO is 1.49 USD. The price increased by 2.05% in the last trading session.
The exchange symbol of AZIYO BIOLOGICS INC-CLASS A is AZYO and it is listed on the Nasdaq exchange.
AZYO stock is listed on the Nasdaq exchange.
7 analysts have analysed AZYO and the average price target is 8.16 USD. This implies a price increase of 447.65% is expected in the next year compared to the current price of 1.49. Check the AZIYO BIOLOGICS INC-CLASS A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AZIYO BIOLOGICS INC-CLASS A (AZYO) has a market capitalization of 24.21M USD. This makes AZYO a Nano Cap stock.
AZIYO BIOLOGICS INC-CLASS A (AZYO) currently has 151 employees.
AZIYO BIOLOGICS INC-CLASS A (AZYO) has a support level at 1.37 and a resistance level at 1.62. Check the full technical report for a detailed analysis of AZYO support and resistance levels.
The Revenue of AZIYO BIOLOGICS INC-CLASS A (AZYO) is expected to decline by -12.95% in the next year. Check the estimates tab for more information on the AZYO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AZYO does not pay a dividend.
AZIYO BIOLOGICS INC-CLASS A (AZYO) will report earnings on 2023-11-13, after the market close.
AZIYO BIOLOGICS INC-CLASS A (AZYO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.25).
ChartMill assigns a fundamental rating of 1 / 10 to AZYO. AZYO has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months AZYO reported a non-GAAP Earnings per Share(EPS) of -2.25. The EPS increased by 22.95% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to AZYO. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 9.47% and a revenue growth -12.95% for AZYO